Tofacitinib in Juvenile Idiopathic Arthritis

Not yet recruiting

• Conditions: Juvenile Idiopathic Arthritis (JIA)
• Interventions: Drug: Tofacitinib

• Registration Number: NCT07211932
• Lead Sponsor: Consorci Sanitari de l'Alt Penedès i Garraf

Brief Summary

This study aims to evaluate, using real-world clinical practice data, the efficacy of tofacitinib in improving the clinical control of juvenile idiopathic arthritis (JIA) after 12 months of treatment.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-10
• Study First Submitted: 2025-10-01
• Study First Submitted QC: 2025-10-01
• Last Update Submitted: 2025-10-01
• Study First Posted: 2025-10-08
• Last Update Posted: 2025-10-08
• Study Start: 2025-12-01
• Primary Completion: 2026-12
• Study Completion: 2026-12-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 58

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Tofacitinib	Tofacitinib	Patients affected by JIA and treated with tofacitinib

Primary Outcome Measures

Name	Time	Method
JADAS-10	Baseline and 12 months	Change in the JADAS-10 score at 12 months of treatment with tofacitinib

Trial Locations

Locations (3)

Hospital Sant Joan de Déu Barcelona; 🇪🇸 Barcelona, Barcelona, Spain

Corporació Sanitària Parc Taulí de Sabadell; 🇪🇸 Sabadell, Barcelona, Spain

Hospital de Vilafranca; 🇪🇸 Vilafranca del Penedès, Barceona, Spain